+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class, Route of Administration, Therapy Line, Regimen Type, Distribution Channel, Care Setting - Global Forecast 2026-2032- Product Image
Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class, Route of Administration, Therapy Line, Regimen Type, Distribution Channel, Care Setting - Global Forecast 2026-2032- Product Image
Sale

Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class, Route of Administration, Therapy Line, Regimen Type, Distribution Channel, Care Setting - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010865
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Obstructive Pulmonary Disease Treatment Market is projected to reach USD 16.05 Billion in 2026. It is expected to continue growing at a CAGR of 7.07%, reaching USD 24.25 Billion by 2032.

Chronic obstructive pulmonary disease treatment is moving from symptom control toward precision-guided, prevention-oriented care. COPD remains one of the world's leading causes of death, with the World Health Organization identifying it as the third leading cause of mortality globally and attributing millions of deaths annually to the disease. The burden is amplified by tobacco exposure, household and ambient air pollution, occupational dusts and fumes, aging populations, recurrent respiratory infections, and delayed diagnosis due to underuse of spirometry.

The treatment landscape includes short- and long-acting bronchodilators, inhaled corticosteroids for selected patients, fixed-dose combination inhalers, phosphodiesterase inhibitors, antibiotics for exacerbation prevention in defined populations, oxygen therapy, pulmonary rehabilitation, vaccination, smoking cessation, and emerging biologic and anti-inflammatory approaches. Demand is increasingly shaped by guideline-based escalation, real-world adherence challenges, inhaler device usability, payer scrutiny, and the need to reduce acute exacerbations, hospitalizations, and mortality.

Transformative Shifts in COPD Care

The COPD treatment landscape is being reshaped by updated GOLD guidance, broader use of dual bronchodilation, and more selective use of inhaled corticosteroids based on exacerbation history, asthma overlap, pneumonia risk, and blood eosinophil counts. Triple therapy has gained clinical relevance for patients with persistent exacerbations, while maintenance bronchodilation remains central to improving lung function, dyspnea, exercise tolerance, and quality of life.

Innovation is also expanding beyond conventional inhalers. Recent regulatory approvals for novel mechanisms, including inhaled PDE3/PDE4 inhibition and biologic therapy for eosinophilic COPD, signal a shift toward phenotype-directed treatment. At the same time, payers and health systems are prioritizing adherence, inhaler technique education, pulmonary rehabilitation access, vaccination coverage, smoking cessation, and early diagnosis because these interventions are strongly linked to reduced exacerbation risk and lower avoidable healthcare utilization.

AI's Cumulative Impact on COPD Treatment

Artificial intelligence is cumulatively strengthening COPD treatment by improving detection, risk stratification, and care coordination. AI-enabled analysis of electronic health records, pharmacy claims, spirometry signals, pulse oximetry, wearables, and imaging can help identify undiagnosed patients, predict exacerbation risk, and flag declining adherence. These tools are especially relevant because COPD is frequently diagnosed late, and exacerbations are associated with accelerated lung function decline, repeated hospital admissions, and higher mortality risk.

AI is also influencing drug development and clinical strategy. Machine learning supports patient phenotyping, trial enrichment, inhaler-use analytics, digital companion apps, virtual pulmonary rehabilitation, and remote monitoring programs. However, adoption depends on clinical validation, interoperability, transparency, privacy safeguards, and equitable performance across age groups, smoking histories, ethnicities, sex, socioeconomic status, and comorbidity profiles. Industry leaders should treat AI as an evidence-generating layer that complements, rather than replaces, guideline-led clinical judgment.

Key Regional Insights

North America represents a high-value COPD treatment region due to strong uptake of branded inhalers, biologics, digital respiratory care, and guideline-based chronic disease management. The United States has a large diagnosed COPD population, high hospitalization costs from exacerbations, and extensive payer influence, while Canada emphasizes public reimbursement, smoking cessation, vaccination, and integrated primary care pathways. Europe is characterized by mature respiratory guidelines, established pulmonary rehabilitation models, air-quality regulation, and centralized cost-effectiveness assessment, with Germany, France, Italy, Spain, and the United Kingdom shaping access decisions through national and regional reimbursement systems.

Asia-Pacific is the fastest-evolving opportunity base because of aging demographics, high tobacco exposure in several markets, biomass fuel exposure, urban air pollution, and expanding access to respiratory diagnostics in China, India, Japan, South Korea, Australia, and ASEAN economies. Latin America, led by Brazil and Mexico, faces high underdiagnosis and uneven specialist access but shows rising demand for affordable combination inhalers and primary care-based respiratory management. The Middle East, including GCC countries, is investing in specialty care capacity, digital health infrastructure, and hospital-based respiratory services, while Africa remains constrained by diagnosis gaps, medicine affordability, limited spirometry availability, and competing infectious respiratory burdens.

Key Group Insights

The European Union continues to influence COPD treatment through evidence-based reimbursement, health technology assessment, air-quality policy, tobacco control measures, and harmonized regulatory standards. G7 countries drive innovation through advanced clinical research ecosystems, higher biologic and digital health adoption, mature payer frameworks, and strong real-world evidence capabilities, while NATO markets overlap substantially with high-income systems that prioritize respiratory resilience, supply continuity, essential medicine access, and chronic disease preparedness.

BRICS countries represent a major patient-access opportunity because China, India, Brazil, Russia, and South Africa combine large populations with substantial exposure to smoking, pollution, biomass fuel, and occupational risk factors. ASEAN markets are expanding through urban hospital networks, greater use of inhaled maintenance therapies, improving respiratory diagnostics, and public health initiatives against tobacco. GCC countries are advancing specialist respiratory services, integrated electronic health records, and digital health infrastructure, but long-term success depends on earlier diagnosis, adherence support, affordability, smoking prevention, and broader access to pulmonary rehabilitation.

Key Country Insights

The United States leads in commercialization of advanced COPD therapies, including novel inhaled medicines, triple combinations, digital adherence solutions, and biologics for eligible patients, supported by extensive specialist networks and payer-managed treatment pathways. Canada maintains strong guideline alignment and public reimbursement pathways, while Mexico and Brazil show growing demand for cost-effective inhaled therapies, expanded spirometry access, and improved primary care detection. In Europe, the United Kingdom, Germany, France, Italy, and Spain remain central to adoption of evidence-based COPD management, although reimbursement criteria, prescribing controls, health technology assessment outcomes, and regional health budgets shape therapy sequencing and access.

China and India are pivotal COPD treatment countries due to large patient pools, air pollution exposure, smoking-related disease, biomass exposure, and expanding healthcare access, but underdiagnosis and uneven spirometry use remain substantial barriers. Japan, South Korea, and Australia demonstrate advanced respiratory care models, high standards for inhaler quality, aging-population management, vaccination integration, and growing use of digital monitoring. Russia presents demand for maintenance inhalers, exacerbation prevention, and hospital-based respiratory care, though access can vary by region, procurement structure, and reimbursement coverage.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value in exacerbation reduction, symptom control, adherence improvement, and safety. Portfolio strategies should align with GOLD-guided treatment pathways, including dual bronchodilation, appropriate triple therapy, phenotype-based use of anti-inflammatory agents, and biologics for eligible eosinophilic COPD populations. Leaders should also invest in inhaler usability, dose counters, patient education, adherence services, and evidence demonstrating fewer hospitalizations, fewer severe exacerbations, and better health-related quality of life.

Commercial success will depend on pairing medicines with services that solve real-world barriers. Recommended actions include expanding spirometry partnerships, supporting smoking cessation and vaccination programs, building AI-enabled risk identification tools, generating local health economic evidence, strengthening pharmacovigilance, and improving access to pulmonary rehabilitation. In emerging markets, affordability, device simplicity, physician training, reliable distribution, and local guideline alignment are critical to sustainable growth.

Research Methodology

This executive summary is built on a structured methodology combining secondary research, primary validation, and data triangulation. Core evidence sources include WHO epidemiology, GOLD strategy reports, regulatory labels and approvals, peer-reviewed clinical trials, real-world evidence studies, health technology assessment documents, national respiratory guidelines, hospital utilization data, public health datasets, and publicly available payer policies.

Market interpretation integrates therapy class assessment, disease burden analysis, pipeline evaluation, reimbursement review, regional access mapping, treatment pathway assessment, and expert-informed validation. Findings are cross-checked across clinical, regulatory, commercial, and public health sources to avoid unsupported claims. The methodology emphasizes verified insights over speculative market sizing, enabling decision-makers to connect COPD treatment trends with evidence-based investment, access, and commercialization priorities.

Conclusion

The COPD treatment market is entering a new phase defined by precision phenotyping, novel anti-inflammatory mechanisms, digitally enabled care, and stronger emphasis on preventing exacerbations. While bronchodilators and combination inhalers remain the foundation of treatment, biologics, inhaled non-steroidal anti-inflammatory therapies, pulmonary rehabilitation, vaccination, and AI-supported care models are broadening the clinical and commercial opportunity.

Sustainable leadership will require more than product innovation. Companies that combine robust clinical evidence, affordability strategies, patient-centered inhaler design, adherence support, real-world data generation, and regional access expertise will be best positioned to improve outcomes. As health systems intensify focus on chronic respiratory disease, COPD treatment will remain a strategic priority across pharmaceuticals, devices, diagnostics, and digital health.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Class
7.1. Anticholinergics
7.2. Beta Agonists
7.3. Corticosteroids
7.4. Methylxanthines
8. Chronic Obstructive Pulmonary Disease Treatment Market, by Route Of Administration
8.1. Nasal
8.2. Intravenous
8.3. Oral
9. Chronic Obstructive Pulmonary Disease Treatment Market, by Therapy Line
9.1. First-Line Therapy
9.2. Second-Line Therapy
9.3. Third-Line And Later Therapy
10. Chronic Obstructive Pulmonary Disease Treatment Market, by Regimen Type
10.1. Monotherapy
10.2. Dual Therapy
11. Chronic Obstructive Pulmonary Disease Treatment Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Chronic Obstructive Pulmonary Disease Treatment Market, by Care Setting
12.1. Inpatient Care
12.2. Outpatient Care
12.3. Homecare
13. North America Chronic Obstructive Pulmonary Disease Treatment Market
14. Europe Chronic Obstructive Pulmonary Disease Treatment Market
15. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market
16. Latin America Chronic Obstructive Pulmonary Disease Treatment Market
17. Africa Chronic Obstructive Pulmonary Disease Treatment Market
18. Middle East Chronic Obstructive Pulmonary Disease Treatment Market
19. NATO Chronic Obstructive Pulmonary Disease Treatment Market
20. G7 Chronic Obstructive Pulmonary Disease Treatment Market
21. European Union Chronic Obstructive Pulmonary Disease Treatment Market
22. BRICS Chronic Obstructive Pulmonary Disease Treatment Market
23. ASEAN Chronic Obstructive Pulmonary Disease Treatment Market
24. GCC Chronic Obstructive Pulmonary Disease Treatment Market
25. United States Chronic Obstructive Pulmonary Disease Treatment Market
26. China Chronic Obstructive Pulmonary Disease Treatment Market
27. Canada Chronic Obstructive Pulmonary Disease Treatment Market
28. Germany Chronic Obstructive Pulmonary Disease Treatment Market
29. Brazil Chronic Obstructive Pulmonary Disease Treatment Market
30. Mexico Chronic Obstructive Pulmonary Disease Treatment Market
31. Japan Chronic Obstructive Pulmonary Disease Treatment Market
32. India Chronic Obstructive Pulmonary Disease Treatment Market
33. United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market
34. France Chronic Obstructive Pulmonary Disease Treatment Market
35. Italy Chronic Obstructive Pulmonary Disease Treatment Market
36. Australia Chronic Obstructive Pulmonary Disease Treatment Market
37. South Korea Chronic Obstructive Pulmonary Disease Treatment Market
38. Russia Chronic Obstructive Pulmonary Disease Treatment Market
39. Spain Chronic Obstructive Pulmonary Disease Treatment Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Adherium Limited
41.2. AptarGroup, Inc.
41.3. Arcede Pharma AB
41.4. AstraZeneca PLC
41.5. Aurobindo Pharma Ltd.
41.6. Boehringer Ingelheim International GmbH
41.7. Chiesi Farmaceutici S.p.A.
41.8. Cipla Ltd.
41.9. GlaxoSmithKline plc
41.10. Glenmark Pharmaceuticals Ltd.
41.11. Grifols, S.A.
41.12. Hikma Pharmaceuticals PLC
41.13. Iconovo AB
41.14. Innoviva, Inc.
41.15. Inogen, Inc.
41.16. Invacare Corporation
41.17. Kamada Ltd.
41.18. Kindeva Drug Delivery
41.19. Koninklijke Philips N.V.
41.20. Lupin Limited
41.21. Medline Industries, LP
41.22. Merck & Co., Inc.
41.23. Mylan N.V.
41.24. Nidek Medical Products, Inc.
41.25. Novartis AG
41.26. Orion Corporation
41.27. PARI Pharma GmbH
41.28. Pfizer Inc.
41.29. Sun Pharmaceutical Industries Ltd.
41.30. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2025 VS 2032 (%)
FIGURE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BETA AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BETA AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BETA AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL METHYLXANTHINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL METHYLXANTHINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL METHYLXANTHINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL THIRD-LINE AND LATER THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL THIRD-LINE AND LATER THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL THIRD-LINE AND LATER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DUAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DUAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DUAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL INPATIENT CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL INPATIENT CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL INPATIENT CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL OUTPATIENT CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL OUTPATIENT CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL OUTPATIENT CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 75. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 77. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 78. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 79. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 80. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 81. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 96. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 98. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 100. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 101. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 110. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 112. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 113. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 114. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 115. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 117. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 119. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 121. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 122. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 131. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 134. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 135. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 136. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 138. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 142. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 143. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 145. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 147. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 149. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 150. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 152. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 153. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 159. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 160. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 161. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 163. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 164. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 165. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 166. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 167. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 168. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 170. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 171. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 173. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 174. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 175. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 177. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 178. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 180. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 181. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 182. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 184. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 185. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 187. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 189. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 191. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 192. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 194. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 195. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 196. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 197. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 198. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 199. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 201. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 202. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 203. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 205. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 206. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 208. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 212. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 213. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 215. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 216. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 217. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 219. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 220. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 221. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 222. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 223. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 224. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 226. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 227. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 229. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 231. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 232. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 233. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 234. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 235. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 236. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 238. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 240. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 241. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 242. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 243. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 244. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 245. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 246. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 247. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 248. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 249. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
TABLE 250. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 251. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 252. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 253. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 254. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
TABLE 255. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 256. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Chronic Obstructive Pulmonary Disease Treatment market report include:
  • Adherium Limited
  • AptarGroup, Inc.
  • Arcede Pharma AB
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Cipla Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Grifols, S.A.
  • Hikma Pharmaceuticals PLC
  • Iconovo AB
  • Innoviva, Inc.
  • Inogen, Inc.
  • Invacare Corporation
  • Kamada Ltd.
  • Kindeva Drug Delivery
  • Koninklijke Philips N.V.
  • Lupin Limited
  • Medline Industries, LP
  • Merck & Co., Inc.
  • Mylan N.V.
  • Nidek Medical Products, Inc.
  • Novartis AG
  • Orion Corporation
  • PARI Pharma GmbH
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages197
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 16.05 Billion
Forecasted Market Value ( USD ) by 2032 $ 24.25 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Chronic Obstructive Pulmonary Disease Therapeutics Market by Product, Disease Severity, Route of Administration, Molecule Type, Age Group, Distribution Channel, End User - Global Forecast 2026-2032 - Product Image

Chronic Obstructive Pulmonary Disease Therapeutics Market by Product, Disease Severity, Route of Administration, Molecule Type, Age Group, Distribution Channel, End User - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Market Report and Forecast 2025-2034 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2026 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Chronic Obstructive Pulmonary Disease Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 100 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.